ORIGINAL RESEARCH
Published on 16 Dec 2024
Monitoring and Management of Adverse Effects Associated with Trastuzumab Deruxtecan: A UAE-specific Consensus
doi 10.3389/fonc.2024.1443962
- 102 views
- Frontiers in Oncology
- Breast Cancer
- Research Topics
- The Exciting Opportunities and Challenges for Targeting “HER2 low” Breast Cancers and Beyond
The Exciting Opportunities and Challenges for Targeting “HER2 low” Breast Cancers and Beyond
1,163
Total Downloads
4,993
Total Views and Downloads
Submit your idea
You will be redirected to our submission process.
Articles
PERSPECTIVE
Published on 22 Nov 2024
The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways
doi 10.3389/fonc.2024.1461190
- 719 views
ORIGINAL RESEARCH
Published on 08 Nov 2024
Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study
doi 10.3389/fonc.2024.1435485
- 473 views
ORIGINAL RESEARCH
Published on 25 Sep 2024
Efficacy and prognosis of neoadjuvant chemotherapy in HER2 low-expressing breast cancer: a retrospective single-center study
doi 10.3389/fonc.2024.1454726
- 341 views
SYSTEMATIC REVIEW
Published on 29 Aug 2024
Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis
doi 10.3389/fonc.2024.1413674
- 605 views
- 1 citation
ORIGINAL RESEARCH
Published on 21 Aug 2024
Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study
doi 10.3389/fonc.2024.1412051
- 591 views
ORIGINAL RESEARCH
Published on 15 Aug 2024
Preliminary study on DCE-MRI radiomics analysis for differentiation of HER2-low and HER2-zero breast cancer
doi 10.3389/fonc.2024.1385352
- 654 views
- 1 citation
Published in
Frontiers in Oncology
- Breast Cancer
Impact
- 4,993Topic views
- 3,090Article views
- 1,163Article downloads